^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DAN-222

    i
    Other names: DAN-222, camptothecin conjugated polymeric nanoparticle
    Company:
    Dantari
    Drug class:
    Topoisomerase I inhibitor
    Related drugs:
    5ms
    A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=30, Completed, Dantari, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative
    |
    Zejula (niraparib) • DAN-222
    7ms
    A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Dantari, Inc. | Recruiting --> Active, not recruiting | N=72 --> 30 | Trial completion date: Dec 2025 --> Oct 2023 | Trial primary completion date: Aug 2025 --> Sep 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative
    |
    Zejula (niraparib) • DAN-222
    10ms
    A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=72, Recruiting, Dantari, Inc. | N=30 --> 72 | Trial completion date: Apr 2024 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Aug 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative
    |
    Zejula (niraparib) • DAN-222
    over1year
    A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Dantari, Inc. | N=96 --> 30 | Trial completion date: Jun 2023 --> Apr 2024
    Enrollment change • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative
    |
    Zejula (niraparib) • DAN-222
    2years
    A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=96, Recruiting, Dantari, Inc.
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative
    |
    Zejula (niraparib) • DAN-222